iShares Biotechnology ETF (NASDAQ:IBB) Hits New 52-Week High – What’s Next?

iShares Biotechnology ETF (NASDAQ:IBB) shares reached a new 52-week high during trading on Monday . The stock traded as high as $199.89 and last traded at $199.61, with a volume of 135462 shares changing hands. The stock had previously closed at $197.71.

iShares Biotechnology ETF Stock Down 0.1%

The business’s fifty day moving average is $185.06 and its two-hundred day moving average is $175.77.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Monday, June 15th were given a $0.0238 dividend. This represents a $0.10 dividend on an annualized basis and a yield of 0.0%. The ex-dividend date was Monday, June 15th.

Institutional Investors Weigh In On iShares Biotechnology ETF

A number of institutional investors and hedge funds have recently made changes to their positions in IBB. Darwin Wealth Management LLC bought a new position in iShares Biotechnology ETF in the second quarter valued at about $25,000. Basepoint Wealth LLC bought a new stake in iShares Biotechnology ETF during the 4th quarter worth about $26,000. Pension & Wealth Management Advisors Inc. acquired a new position in iShares Biotechnology ETF during the 2nd quarter valued at about $28,000. Cary Street Partners Financial LLC acquired a new position in iShares Biotechnology ETF during the 4th quarter valued at about $29,000. Finally, Copia Wealth Management bought a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at about $34,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.